BMEA - Biomea Fusion Inc Debt to Book Capitalization Ratio

Biomea Fusion, Inc. (BMEA) serves as a leading developer of covalent compounds to combat metabolic disorders and diabetes, backed by significant scientific weight. This price trend reflects the asset's dynamics, with its current value standing at 0.07. The company's projects focus on creating targeted therapies for oncology and endocrine pathologies. Under Thomas Butler's leadership, the firm is currently navigating critical trial stages, which is driving moderate volatility in the share price.

BMEA (Biomea Fusion Corp) Debt to Book Value history from 07/04/2022 to 10/28/2026

Biomea Fusion Inc (BMEA) - metric breakdowns and financial figures

- price and consensus price forecast:

Stock Price Biomea Fusion, Inc.|BMEA - Analyst Consensus Forecast

- market capitalization data:

Market Value Biomea Fusion Corp|BMEA - Value Adjusted for Debt and Cash

- book capitalization data:

Net Assets per Single Share Biomea Fusion|BMEA - Company Net Assets|Market Capitalization to Book Value Ratio biomeafusion.com|BMEA - Company Total Assets

- debt and liquidity data:

Total Debt to Equity Ratio Biomea Fusion, Inc.|BMEA - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Biomea|BMEA - Company Total Debt|Debts to Book Capitalization Biomea Fusion Corp

Fundamental company analysis:Biomea Fusion, Inc. - BMEA

This indicator measures the proportion of borrowed funds relative to equity, allowing for an assessment of financial leverage and the extent of the business's dependence on creditors. The stability of the healthcare sector and the insulation of Biomea Fusion, Inc. (BMEA) research from geopolitics make the company's debt relative to its book capitalization a reliable marker of resilience, confirming low default risks during the development of innovations.

Competitors of Biomea Fusion, Inc. (BMEA)